Full-Time

Associate Director of Supply Chain Finance

Confirmed live in the last 24 hours

Syndax

Syndax

201-500 employees

Develops cancer therapies and conducts clinical trials

Biotechnology
Healthcare

Senior

Remote in USA

Category
Supply Chain Management
Operations & Logistics
Required Skills
Supply Chain Management
Inventory Management
Financial analysis
Data Analysis
Requirements
  • Bachelor’s degree in Finance, Accounting, Supply Chain Management, Business Administration, or a related field; MBA or relevant advanced degree preferred.
  • 8+ years of experience in supply chain finance, accounting, financial analysis, or related roles, with a focus on strategic leadership within Pharmaceutical Industry.
  • Proven track record of successfully managing financial operations in a supply chain environment.
  • Strong analytical skills and expertise in financial modeling, with proficiency in data analysis tools (e.g., Excel, ERP systems).
  • Exceptional communication and interpersonal skills, with the ability to influence and collaborate with stakeholders at all levels.
  • Detail-oriented with robust organizational and problem-solving abilities.
  • In-depth knowledge of supply chain processes, financial principles, and accounting standards.
  • Experience with standard cost calculations and product costing methodologies.
  • Proven ability to work collaboratively as a business partner, across all functions in a fast-paced, high growth environment.
  • Intellectually curious and challenges status quo thinking to drive good analytics in support of the business; able to constantly challenge internal business partners on business assumptions and plans.
  • Works effectively in a matrix environment motivating and obtaining support from others with/or without direct reporting lines.
Responsibilities
  • Lead the financial planning, budgeting, and forecasting processes for the supply chain, ensuring alignment with overall business objectives.
  • Develop and implement financial models and analyses to support inventory management, procurement, and logistics strategies.
  • Perform standard cost calculations to ensure accurate product costing and assist in pricing strategies.
  • Collaborate with senior management and cross-functional teams to provide financial insights that influence decision-making and enhance supply chain performance.
  • Oversee monthly, quarterly and year-end closing activities, ensuring accurate period-end accruals, account reconciliations and journal entries related to supply chain transactions.
  • Ensure precise allocation of costs to inventory and maintain oversight of inventory valuations and working capital management.
  • Prepare and present financial reports and dashboards for senior leadership, highlighting key performance indicators and actionable recommendations.
  • Lead initiatives to improve supply chain financial processes, identifying risks and opportunities to enhance profitability.
  • Ensure compliance with accounting standards and regulatory requirements and uphold best practices in financial operations.

Syndax Pharmaceuticals develops and commercializes therapies specifically for cancer patients, focusing on challenging cases like hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The company conducts research and clinical trials to test the safety and effectiveness of its drugs, aiming to bring them to market after receiving regulatory approval. Syndax's main product, Entinostat, is currently in clinical trials combined with Exemestane for treating HR+, HER2- breast cancer. Unlike many competitors, Syndax targets underserved patient populations and relies on strategic partnerships and public offerings to fund its research and development. The goal is to advance cancer treatment by developing new therapies that address the needs of patients with difficult-to-treat cancers.

Company Stage

IPO

Total Funding

$144.3M

Headquarters

Waltham, Massachusetts

Founded

2005

Growth & Insights
Headcount

6 month growth

30%

1 year growth

51%

2 year growth

154%
Simplify Jobs

Simplify's Take

What believers are saying

  • Positive clinical trial results for revumenib in combination therapies suggest strong potential for regulatory approval and market success.
  • The appointment of experienced professionals like Aleksandra Rizo to the board of directors enhances the company's strategic direction and clinical development capabilities.
  • Syndax's inducement grants and stock options for new employees indicate a commitment to attracting and retaining top talent, fostering a culture of innovation.

What critics are saying

  • The highly competitive oncology market requires continuous innovation and successful clinical trials to maintain a competitive edge.
  • Dependence on the success of key products like Entinostat and revumenib means that any setbacks in clinical trials or regulatory approvals could significantly impact the company's growth.

What makes Syndax unique

  • Syndax focuses on developing therapies for difficult-to-treat cancers, particularly HR+, HER2- breast cancer, setting it apart from competitors with broader oncology portfolios.
  • The company's flagship product, Entinostat, and its innovative pipeline, including revumenib and axatilimab, highlight its commitment to targeting specific cancer pathways and patient populations.
  • Syndax's strategic capital raises and public offerings provide robust financial support for its R&D efforts, unlike competitors who may struggle with funding.

Help us improve and share your feedback! Did you find this helpful?